Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.76
  • Today's Change0.07 / 2.60%
  • Shares traded196.36k
  • 1 Year change-81.79%
  • Beta2.2371
Data delayed at least 15 minutes, as of Jul 05 2022 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

  • Revenue in USD (TTM)42.94m
  • Net income in USD-134.24m
  • Incorporated2000
  • Employees345.00
  • Location
    Cellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
  • Phone+33 181691600
  • Fax+33 181691606
  • Websitehttp://www.cellectis.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tcr2 Therapeutics Inc0.00-107.42m111.40m145.00--0.4363-----2.80-2.800.006.620.00----0.00-29.86-34.17-31.68-35.77------------0.00-------48.69--67.47--
Axcella Health Inc0.00-68.48m111.46m59.00--3.73-----1.75-1.750.000.56860.00----0.00-84.09---98.22-------------23.740.4566-------14.33------
Marizyme Inc136.33k-14.91m111.46m11.00--2.46--817.58-0.3943-0.39430.00371.110.00251.656.1412,393.64-27.22-13.22-27.83-13.5463.6853.55-10,937.39-3,540.212.22-24.920.0132--6.67-6.30-88.16------
Applied Molecular Transport Inc.0.00-122.40m112.10m150.00--0.8768-----3.18-3.180.003.310.00----0.00-79.46---87.22--------------0.0055-------50.66------
Trevi Therapeutics Inc0.00-32.90m112.96m24.00--8.60-----1.34-1.340.000.33960.00----0.00-89.82-77.24-119.53-99.95-----------28.000.5754-------3.61------
Vascular Biogenics Ltd696.00k-34.07m113.04m41.00--2.64--162.41-0.4669-0.46690.00960.61720.0135----16,975.61-65.91-38.15-79.61-43.9152.5990.56-4,894.40-623.77----0.00---16.70---23.51--24.44--
Chromadex Corp70.03m-27.49m114.12m115.00--4.40--1.63-0.4029-0.40291.030.37971.151.9411.71608,913.10-45.09-58.04-65.86-83.2361.1057.17-39.25-57.161.56-623.700.0007--13.8225.50-36.15---25.01--
Praxis Precision Medicines Inc0.00-208.41m114.23m139.00--0.598-----4.69-4.690.004.200.00----0.00-80.35---90.65--------------0.00-------137.56------
Cellectis SA (ADR)42.94m-134.24m114.29m345.00--0.6404--2.66-2.97-2.970.9514.200.1087--3.04124,455.10-36.59-24.90-44.41-30.71---29.56-336.58-232.72----0.3221---18.663.51-40.86---18.03--
Humanigen Inc4.15m-192.36m115.84m11.00------27.95-3.18-3.180.0671-0.35810.0487----376,818.20-226.08-337.54-841.16-8,136.81-----4,640.77-9,482.19---63.41174.95--1,052.24---164.31------
Greenwich Lifesciences Inc0.00-5.94m116.48m3.00--5.95-----0.453-0.4530.001.510.00----0.00-23.69---24.13--------------0.00-------145.34------
Adverum Biotechnologies Inc0.00-155.01m116.55m188.00--0.4119-----1.58-1.580.002.860.00----0.00-35.68-30.60-37.54-32.32-------3,979.52----0.00----38.82-23.86--44.36--
Coeptis Therapeutics Inc0.00-30.68m116.85m4.00--49.66-----0.8543-0.85430.000.06080.00----0.00-691.69---12,413.82----------0.8664-134.930.6202--------------
Rezolute Inc0.00-38.13m117.20m26.00--1.05-----3.15-3.150.003.340.00----0.00-74.39-193.04-79.40-292.62-----------21.950.2158-------2.80------
RVL Pharmaceuticals PLC38.01m-75.90m117.81m156.00--1.69--3.10-1.11-0.89030.52370.8320.15220.57152.00243,653.80-30.39-18.78-35.34-21.8686.6351.85-199.68-61.822.75-11.310.4015---90.16-39.64-4.10---35.47--
Otonomy Inc35.00k-52.52m117.83m51.00--2.72--3,366.51-0.7805-0.78050.00050.75980.0004----686.27-60.15-48.91-68.25-53.87-300.00-108.19-150,065.70-9,435.55---32.100.274---54.21-28.80-14.42---35.02--
Data as of Jul 05 2022. Currency figures normalised to Cellectis SA's reporting currency: US Dollar USD

Institutional shareholders

22.18%Per cent of shares held by top holders
HolderShares% Held
Long Focus Capital Management LLCas of 31 Mar 20222.54m5.59%
Capital Research & Management Co. (International Investors)as of 31 Mar 20221.59m3.50%
Credit Suisse Asset Management (Schweiz) AGas of 31 Mar 20221.44m3.16%
Principal Global Investors LLCas of 31 Mar 20221.21m2.67%
Baillie Gifford & Co.as of 31 Mar 20221.08m2.38%
Capital Research & Management Co. (World Investors)as of 31 Mar 2022621.07k1.37%
Jane Street Capital LLCas of 31 Mar 2022603.25k1.33%
Millennium Management LLCas of 31 Mar 2022402.90k0.89%
D. E. Shaw & Co. LPas of 31 Mar 2022299.69k0.66%
BlackRock Fund Advisorsas of 31 Mar 2022287.29k0.63%
More ▼
Data from 31 Mar 2022 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.